The FSD BioScience Division is focused on developing a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract and the musculoskeletal system

Research Areas

FSD BioSciences is focused on advancing research and development of synthetic cannabinoids and compounds that target the endocannabinoid system.

Potential indication areas:

  • Central Nervous System (CNS) disorders
  • Chronic pain, including opioid-sparing
  • Dermatological conditions
  • Women’s health
  • GI tract

Prismic Pharmaceuticals

Prismic Pharmaceuticals was acquired by FSD Pharma in June 2019. Prismic is a US-based specialty pharmaceutical company dedicated to developing novel non-addictive prescription drugs for the treatment of pain and inflammation.

Learn More »